^
Association details:
| Biomarker: | MYD88 L265P |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia
Published date:
11/01/2018
Excerpt:
We therefore initiated a phase II study to evaluate the safety and efficacy of venetoclax monotherapy in previously treated patients with WM (NCT02677324)....All patients carried the MYD88L265P mutation….At best response, very good partial response (VGPR) was attained in 5 patients (17%), partial response in 19 (63%), minor response in 2 (7%) and stable disease in 4 (13%), for an overall response rate of 87% and major response rate of 80%.
DOI:
10.1182/blood-2018-99-112325
Trial ID:
Source:
Title:
PROSPECTIVE PHASE II STUDY OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED WALDENSTROM MACROGLOBULINEMIA (WM)
Published date:
05/17/2018
Excerpt:
We initiated a phase II study to evaluate the safety and efficacy of ven monotherapy in previously treated pts with WM (NCT02677324)….The MYD88L265P mutation was detected in all pts, and CXCR4 mutations in 16 (53%)…. At best response, very good partial response (VGPR) was attained in 5 pts (17%), partial response in 11 (37%), minor response in 8 (27%) and stable disease in 6 (20%), for overall response rate of 80% and major response rate of 53%.
Trial ID:
Source:
Title:
Venetoclax in Previously Treated Waldenström Macroglobulinemia
Excerpt:
All patients were MYD88 L265P–mutated...Venetoclax is safe and highly active in patients with previously treated WM...
DOI:
10.1200/JCO.21.01194
Trial ID:
